After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

Tech provider Signant Health announced the acquisition of Ametris to unite its electronic clinical outcome assessments (eCOA) ...

Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks ...

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year ...